造血干细胞（Hematopoietic stem cells, HSCs）移植是治疗心肌梗死等缺血性疾病的有效措施。干细胞移植后往往在短期损失，是干细胞移植疗法急需解决的问题。为了促进干细胞的植入与存活，我们前期研究发现，温敏性水凝胶作为细胞载体具备温度可控性、构型可塑性等优势，能防止移植细胞短期损失。因此，我们提出使用温敏性水凝胶作为载体移植HSCs到梗死心肌的可能性。我们也发现使用无基质培养法能扩增足够的供体HSCs，在移植前基因修饰的HSCs可促进其存活和分化，但是，其在心肌梗死中的疗效尚未明确。本项目拟合成温敏性水凝胶，封装HSCs或基因修饰的HSCs，移植到动物梗死心肌，观察HSCs的植入、存活和分化能力，并评估心肌修复与血管生成情况，探讨水凝胶载体移植HSCs治疗心肌梗死的疗效，为心肌梗死的干细胞疗法提供新的思路和实验依据。

Hematopoietic stem cells (HSCs) transplantation is an effective treatment for myocardial infarction and other ischemic diseases. However, the stems cells tend to lose soon after transplantation, which hinder the application of cell therapy of myocardial infarction. In order to enhance the implantation and survival of stem cells, our previous studies have found that the thermosensitive hydrogel could act as a cell carrier with a temperature-controlled character and conformational plasticity, to prevent the short-term lost of the transplanted cells. Thus, we propose the possibility of using thermosensitive hydrogel as a cell carrier to transplant HSCs to the infarct myocardium. In addition, we have found that using stromal-free culture expand substantial HSCs, and genetically modifying HSCs can promote their survival and differentiation. But its efficacy in myocardial infarction is not yet clear. Therefore, in this project we will synthesize thermosensitive hydrogel to encapsulate HSCs or genetically modified HSCs, then transplant it into animal infarct heart. We will observe the the implantation, survival and differentiation of HSCs, and assess myocardial repair and angiogenesis, in order that we can evaluate the efficacy of using hydrogel to transplant HSCs to infarct heart, and provide new ideas and experimental evidence for stem cell therapy of myocardial infarction.